NACE - China

NACE
Benefits
Indications

What is NACE?

NACE is a non-invasive prenatal screening test that analyzes the most frequent chromosomal abnormalities without compromising the pregnancy from week 10.

A simple fetal blood draw from the mother allows free DNA circulating in the maternal bloodstream to be detected via next-generation sequencing (NGS) technology and prop

What is the procedure?

What happens in the case of a positive result?

Genetic counseling post-test.
Comprehensive ultrasound examination.
Results confirmation by genetic diagnostic testing (amniocentesisor CVS)

Depending on the screening results, diagnostic testing approach should be karyotype and:

Rapid prenatal testing by qfPCR
Rapid prenatal testing by FISH
Microarrays for prenatal diagnosis

What does NACE detect?

NACE detects abnormalities in chromosomes 21, 18, 13 and the most common anomalies in the sexual chromosomes (X and Y).
NACE 24 analyzes all chromosomes
NACE 24 Extended analyzes all 24 chromosomes and identifies microdeletions associated with 6 major genetic syndromes.

Why use a non-invasive prenatal test

Non – invasive tests can prevent the need for about 98% of invasive tests in patients at risk for trisomy 21.
Reduces the number of miscarriages caused by amniocentesis or corionic villus sampling.
Can give results with fetal fraction under 4%.
Highest informativeness rate in the market: we obtain results for 99.9% of the analyzed samples.
NACE® Extended 24 incorporates the detection of all 24 chromosomes and identifies five microdeletions that are associated with major genetic syndromes.
More reliable than 1st trimester combined screening: Conventional tests including biochemical screening can lead to 1 in every 20 women who test positive for Down syndrome will not be carrying an affected baby.
Avoid a false sense of security: Of every 20 women carrying a baby with Down syndrome, 3 will test negative by biochemical screening.

Who is NACE suitable for?

Several scientific support the use of the NACE test for all pregnant women.
It is particularly recommended for women with:

An abnormal result in their first-trimester screen.
A previous Down´s syndrome pregnancy
A suspicious ultrasound finding.

Test Limitations

cfDNA screening is considered a screening test and not a diagnostic test.
False non-invasive prenatal screening (NIPT) results: fetoplacental mosaicism, maternal chromosomal abnormalities, vanishing twin syndrome and/or errors associated with the procedures.
Low-molecular-weight heparin can interfere with the analysis. If the patient is taking heparin during pregnancy, the recommendation is to perform the blood draw before heparin administration.

Documentation

Specialists’ documents

Clinical Sheets

Download

Brochure

Download

Scientific evidence

Relevant related studies:

Milan M, Mateu E, Blesa D, Clemente-Ciscar M, Simon C. Fetal sex determination in twin pregnancies using cell free fetal DNA analysis. Prenat Diagn. 2018 Apr 23.

Gregg AR et al. Genet Med 2016; 18:1056-65.

Bianchi et al. N Engl J Med. 2014 27;270 (9):799-808.

Nicolaides KH. Prenat Diagn 2011; 31:7-15-